Alturki Abdullah A, Alshammari Nayf A, Alsebayel Firas M, Alhandi Ali A
Department of Orthopedic Surgery, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Department of Orthopedic Surgery, Alhabib Medical Group, Riyadh, Saudi Arabia.
J Surg Case Rep. 2019 Nov 15;2019(11):rjz274. doi: 10.1093/jscr/rjz274. eCollection 2019 Nov.
Myelofibrosis is a myeloproliferative disease that falls under a group of bone marrow malignancies known as myeloproliferative neoplasms. It manifests with splenomegaly, anemia, leukocytosis and, less commonly, bone pain. Ruxolitinib, Janus kinase inhibitor, has been shown to increase survival, to improve symptoms and has the potential to decrease osteosclerotic changes. Herein, we present a case of primary myelofibrosis (PMF) in a 60-year-old female who presented with 8-month history of progressive left hip pain and later was diagnosed with pathological neck of femur fracture that was treated with cementless hemiarthroplasty. In conclusion, the use of cementless implants in hip arthroplasty in the presence of PMF has shown to be an effective and safe choice.
骨髓纤维化是一种骨髓增殖性疾病，属于骨髓增殖性肿瘤这一骨髓恶性肿瘤类别。其表现为脾肿大、贫血、白细胞增多，较少见的还有骨痛。鲁索替尼，一种Janus激酶抑制剂，已被证明可提高生存率、改善症状，并有可能减少骨硬化改变。在此，我们报告一例60岁女性原发性骨髓纤维化（PMF）病例，该患者有8个月进行性左髋部疼痛病史，后来被诊断为股骨颈病理性骨折，并接受了非骨水泥半髋关节置换术治疗。总之，在PMF患者中使用非骨水泥植入物进行髋关节置换术已被证明是一种有效且安全的选择。
